Acrotech Biopharma Drug Patent Portfolio
Acrotech Biopharma owns 5 orange book drugs protected by 14 US patents with Fusilev having the least patent protection, holding only 1 patent. And Evomela with maximum patent protection, holding 7 patents. Given below is the list of Acrotech Biopharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541012 | Compositions comprising disodium levofolinate | 25 Mar, 2039 | Active |
| US10040872 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 30 Jan, 2034 | Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US10940128 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same | 14 Jun, 2030 | Active |
| US10864183 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | 28 May, 2030 | Active |
| US11020363 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | 28 May, 2030 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8835501 | Pharmaceutical formulations of HDAC inhibitors | 27 Oct, 2027 | Active |
| US6888027 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | 10 Aug, 2026 | Active |
| US7622470 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | 31 May, 2025 | Active |
| US8299078 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | 31 May, 2025 | Active |
| US6028071 | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors | 16 Jul, 2022 | Expired |
| US6500829 | Substantially pure diastereoisomers of tetrahydrofolate derivatives | 07 Mar, 2022 | Expired |
Latest Legal Activities on Acrotech Biopharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acrotech Biopharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jun, 2024 | US10864183 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Apr, 2024 | US8299078 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 May, 2023 | US9200088 |
|
Email Notification
Critical
| 31 Mar, 2023 | US11541012 |
|
Electronic Review
Critical
| 31 Mar, 2023 | US11541012 |
| Mail O.P. Petition Decision | 31 Mar, 2023 | US11541012 |
|
Mail-Petition Decision - Dismissed
Critical
| 27 Mar, 2023 | US11541012 |
|
Petition Decision - Dismissed
Critical
| 24 Mar, 2023 | US11541012 |
| O.P. Petition Decision | 08 Mar, 2023 | US11541012 |
|
Petition Decision - Accept Late Payment of Maintenance Fees - Granted
Critical
| 02 Mar, 2023 | US8835501 |
|
Petition to Accept Late Payment of Maintenance Fee Payment Filed
Critical
| 02 Mar, 2023 | US8835501 |
|
Surcharge, Petition to Accept Pymt After Exp, Unintentional
Critical
| 02 Mar, 2023 | US8835501 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 02 Mar, 2023 | US8835501 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Mar, 2023 | US8835501 |
Acrotech Biopharma's Drug Patent Litigations
Acrotech Biopharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 09, 1998, against patent number US6500829. The petitioner , challenged the validity of this patent, with WOOD et al as the respondent. Click below to track the latest information on how companies are challenging Acrotech Biopharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6500829 | March, 1998 |
Decision
(28 Sep, 2001)
| WOOD et al | |
Acrotech Biopharma's Family Patents
Acrotech Biopharma Drug List
Given below is the complete list of Acrotech Biopharma's drugs and the patents protecting them.
1. Beleodaq
Beleodaq is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8835501 | Pharmaceutical formulations of HDAC inhibitors |
27 Oct, 2027
(2 years from now)
| Active |
| US6888027 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
10 Aug, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Beleodaq's drug page
2. Evomela
Evomela is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10040872 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
30 Jan, 2034
(9 years from now)
| Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(8 years from now)
| Active |
| US10940128 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
14 Jun, 2030
(5 years from now)
| Active |
| US10864183 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
28 May, 2030
(5 years from now)
| Active |
| US11020363 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
28 May, 2030
(5 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evomela's drug page
3. Folotyn
Folotyn is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7622470 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
31 May, 2025
(5 months from now)
| Active |
| US8299078 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin |
31 May, 2025
(5 months from now)
| Active |
| US6028071 | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
16 Jul, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Folotyn's drug page
4. Fusilev
Fusilev is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6500829 | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
07 Mar, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fusilev's drug page
5. Khapzory
Khapzory is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541012 | Compositions comprising disodium levofolinate |
25 Mar, 2039
(14 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Khapzory's drug page